List of Excipients in Branded Drug GOOD NEIGHBOR PHARMACY EYE ITCH RELIEF

Generic Drugs Containing GOOD NEIGHBOR PHARMACY EYE ITCH RELIEF

Company	Ingredient	NDC	Excipient
Dispensing Solutions Inc	ketotifen fumarate	68258-8900	GLYCERIN
Dispensing Solutions Inc	ketotifen fumarate	68258-8900	HYDROCHLORIC ACID
Dispensing Solutions Inc	ketotifen fumarate	68258-8900	SODIUM HYDROXIDE
Dispensing Solutions Inc	ketotifen fumarate	68258-8900	WATER

What are the Most Frequently-Used Excipients in GOOD NEIGHBOR PHARMACY EYE ITCH RELIEF?

# Of NDCs	Excipient
1	GLYCERIN
1	HYDROCHLORIC ACID
1	SODIUM HYDROXIDE
1	WATER

Good Neighbor Pharmacy Eye Itch Relief: Excipient Strategy and Commercial Opportunities

Last updated: August 16, 2026

Good Neighbor Pharmacy Eye Itch Relief is a private-label ophthalmic product positioned against branded ketotifen allergy drops such as Zaditor and Alaway. The commercial opportunity is based on low-cost delivery, retail distribution, preservative positioning, package differentiation, and line extensions rather than new-molecule exclusivity.

The product is generally marketed as ketotifen fumarate ophthalmic solution equivalent to ketotifen 0.025%, an antihistamine indicated for temporary relief of itchy eyes caused by pollen, ragweed, grass, animal hair, or dander. Exact inactive ingredients and regulatory ownership can vary by National Drug Code and contract manufacturer, so commercial diligence should be performed at the package and NDC level.

What is Good Neighbor Pharmacy Eye Itch Relief?

Good Neighbor Pharmacy Eye Itch Relief is a store-brand ophthalmic allergy product. The commercially relevant formulation is typically:

Attribute	Product profile
Brand	Good Neighbor Pharmacy Eye Itch Relief
Active ingredient	Ketotifen fumarate equivalent to ketotifen 0.025%
Dosage form	Sterile ophthalmic solution
Therapeutic class	Topical ocular antihistamine
Primary indication	Temporary relief of itchy eyes associated with ocular allergies
Typical dosing	One drop in the affected eye twice daily, generally for users aged 3 years and older
Market position	Lower-priced alternative to branded ketotifen products
Distribution	Independent pharmacy and wholesaler channels associated with Good Neighbor Pharmacy
Regulatory category	OTC ophthalmic allergy product
Primary competitive risks	Branded ketotifen, generic store brands, preservative-free products, artificial tears, and prescription allergy drops

Ketotifen provides a differentiated OTC proposition because it is dosed twice daily and is intended to relieve itching directly. Artificial tears and mast-cell stabilizer products compete for the same consumer need but have different onset, dosing, and labeling profiles.

What excipients are used in Good Neighbor Pharmacy Eye Itch Relief?

Publicly marketed ketotifen ophthalmic solutions commonly use a simple aqueous excipient system. The formulation may include purified water, glycerin, benzalkonium chloride, and pH-adjusting agents such as hydrochloric acid or sodium hydroxide.

Excipient category	Likely function	Commercial and technical relevance
Purified water	Vehicle	Determines solvent quality, microbial control, and manufacturing cost
Glycerin	Tonicity and comfort agent	Can reduce stinging and improve ocular tolerability
Benzalkonium chloride	Preservative	Supports multidose packaging but creates chronic-use and ocular-surface concerns
Hydrochloric acid or sodium hydroxide	pH adjustment	Controls drug solubility, comfort, and stability
Container-closure system	Sterility and dose delivery	Affects leakage, compatibility, usability, and shelf life

The formulation objective is not simply to dissolve ketotifen. It must maintain sterility, preserve the active ingredient throughout shelf life, minimize ocular irritation, support reliable drop formation, and comply with ophthalmic manufacturing requirements.

Why glycerin matters in the formulation

Glycerin is a commercially useful excipient because it can contribute to isotonicity and reduce the discomfort associated with an aqueous ophthalmic product. Its inclusion also supports a smoother consumer experience without materially increasing formulation complexity.

The concentration must remain compatible with ketotifen solubility, viscosity, drop size, microbial-control requirements, and preservative performance. Excessive viscosity can create blurred vision, slow drainage, or inconsistent dosing.

Why benzalkonium chloride is commercially important

Benzalkonium chloride is widely used in multidose ophthalmic products because it provides preservative activity at low concentration. Its principal commercial advantage is compatibility with conventional low-cost multidose bottles.

Its limitation is cumulative ocular-surface exposure. Patients with chronic allergy symptoms, dry eye, contact-lens use, or frequent dosing may prefer preservative-free products. This creates an opportunity for a premium line extension but also introduces higher packaging and manufacturing costs.

Why pH adjustment is a protected process variable

Hydrochloric acid and sodium hydroxide are usually not product differentiators by themselves. Their concentration, however, influences pH, ketotifen stability, patient comfort, preservative efficacy, and extractables or leachables behavior.

A narrow pH target can improve tolerability, but any change requires stability, preservative-effectiveness, container-closure, and bioequivalence or equivalence support appropriate to the regulatory pathway.

What formulations are protected by ketotifen ophthalmic patents?

The commercial product is unlikely to depend on an active, enforceable patent estate for ordinary ketotifen 0.025% ophthalmic solution. Ketotifen ophthalmic products have been marketed for years, and the core active ingredient and conventional aqueous formulation are mature technologies.

Potentially protectable features include:

• Preservative-free ketotifen solutions.
• Multidose preservative-free delivery systems.
• Specific pH and buffer systems.
• Low-irritation formulations with reduced benzalkonium chloride exposure.
• Improved drop-size control.
• Unit-dose or multidose container systems.
• Suspension or emulsion technologies, if technically justified.
• Extended stability under elevated temperature conditions.
• Combination products containing ketotifen and another ocular active.
• Packaging that limits microbial ingress after opening.

A formulation patent must claim more than the presence of ketotifen in water. The strongest claims would generally require a defined concentration range, excipient combination, pH range, stability result, preservative profile, container system, or clinically meaningful tolerability result.

What is the Orange Book status of Good Neighbor Pharmacy Eye Itch Relief?

Good Neighbor Pharmacy Eye Itch Relief is an OTC private-label product and is not ordinarily evaluated through the same Orange Book framework used for prescription generic drugs approved under abbreviated new drug applications.

The commercial consequences are material:

Issue	Relevance to Good Neighbor Pharmacy Eye Itch Relief
Orange Book listing	Usually not the principal source of market protection for an OTC store-brand product
Paragraph IV challenge	Generally not the principal entry mechanism for a conventional OTC private-label product
Hatch-Waxman exclusivity	Limited relevance unless the product is tied to an approved NDA or abbreviated pathway
Patent term extension	Not a primary commercial driver for the mature ketotifen product
OTC labeling	Central competitive requirement
Manufacturing compliance	Critical; sterile ophthalmic products face high quality and recall risk
Private-label rights	Often governed by supply, manufacturing, trademark, and distribution agreements

For diligence, the relevant documents are the product label, NDC listing, FDA establishment information, manufacturing agreement, product-quality records, and any applicable FDA approval or monograph basis.

When does Good Neighbor Pharmacy Eye Itch Relief lose exclusivity?

The product does not have conventional brand exclusivity comparable to a newly approved prescription drug. Its commercial protection comes from private-label branding, retail placement, supply arrangements, quality consistency, and price.

A competing manufacturer can generally commercialize a comparable ketotifen product if it satisfies the applicable FDA requirements and does not infringe valid patents or proprietary packaging rights. The principal barriers are operational rather than exclusivity-based:

1. Sterile ophthalmic manufacturing capacity.
2. Validated filling and inspection processes.
3. Reliable preservative and container-closure performance.
4. FDA-compliant labeling.
5. Retail distribution access.
6. Consistent supply during seasonal demand spikes.
7. Product liability and recall controls.

The product is therefore vulnerable to rapid substitution at the shelf level. A branded private-label position can be displaced by a cheaper supplier, a preservative-free alternative, or a retailer’s own national sourcing program.

What excipient strategy creates the strongest commercial opportunity?

The most attractive strategy is a two-tier portfolio rather than a single reformulation.

Core value product: preserved multidose solution

The existing type of formulation should remain the low-cost anchor. Its advantages are:

• Lowest unit cost.
• Familiar bottle format.
• Efficient high-volume filling.
• Broad pharmacy-channel compatibility.
• Simple consumer instructions.
• Lower packaging cost than unit-dose systems.

The core product should focus on drop consistency, low leakage, clear labeling, and stable supply. Any excipient change should be justified by measurable improvements in tolerability or shelf life.

Premium product: preservative-free ketotifen

A preservative-free version could target consumers with:

• Frequent seasonal dosing.
• Dry-eye symptoms.
• Contact-lens use.
• Sensitivity to benzalkonium chloride.
• Preference for premium ocular products.

The main challenge is multidose sterility after opening. A standard bottle without preservative is commercially difficult because repeated use creates microbial-contamination risk. Suitable approaches include:

• Unit-dose vials.
• One-way valve bottles.
• Filtered multidose dispensers.
• Airless or mechanically protected systems.
• Packaging with microbial ingress control.

This line extension could command a higher retail price, but the added cost of specialized packaging may reduce margin unless the product is positioned as a premium eye-care product.

Comfort-focused formulation

A comfort-oriented product could use an optimized tonicity system and controlled pH while retaining the same active concentration. The claims would need to remain within permitted OTC labeling unless supported through an appropriate regulatory pathway.

Potential consumer messages include reduced stinging, smoother drop delivery, or compatibility with sensitive eyes. Claims about superior tolerability require controlled comparative evidence and careful advertising review.

How does Good Neighbor Pharmacy Eye Itch Relief compare with branded ketotifen products?

Product type	Active ingredient	Typical dosing	Preservative issue	Commercial position
Good Neighbor Pharmacy Eye Itch Relief	Ketotifen 0.025%	Twice daily	Commonly preserved in multidose format	Value/private label
Branded ketotifen product	Ketotifen 0.025%	Twice daily	Preserved or preservative-free, depending on product	Brand and convenience
Cromolyn or other mast-cell stabilizer	Different active	Often more frequent	Product-specific	Alternative allergy therapy
Artificial tears	Lubricating agents	As needed	Preserved or preservative-free	Symptom support, not equivalent antihistamine therapy
Prescription antihistamine/mast-cell stabilizer	Various actives	Product-specific	Often preserved	Higher-value clinical segment

The store-brand product’s principal advantage is price. Its principal weakness is limited differentiation. A private-label manufacturer can improve competitiveness through packaging, preservative-free delivery, better drop control, and a broader ocular-allergy portfolio.

What manufacturing and intellectual-property barriers affect the product?

Sterile ophthalmic manufacturing is the main barrier. A formulation that appears simple still requires validated control of:

• Bioburden and sterilization.
• Aseptic processing.
• Fill volume.
• Drop-size uniformity.
• Particulate matter.
• Container-closure integrity.
• Preservative concentration.
• Extractables and leachables.
• In-use stability.
• Shipping and temperature excursions.

The most defensible IP opportunity is likely to reside in delivery technology rather than basic excipients. A manufacturer could seek patent protection around a preservative-free multidose package, a controlled-drop actuator, or a specific formulation-packaging combination.

Trade secrets may be more valuable than patents for manufacturing parameters, filling conditions, inspection thresholds, and supplier qualification. Private-label agreements can also create practical exclusivity through retailer-specific packaging, forecast commitments, and channel arrangements.

Which companies are challenging the market?

The competitive set includes:

• Branded ketotifen manufacturers.
• National generic ophthalmic companies.
• Retailer-owned private labels.
• Contract manufacturers supplying pharmacy wholesalers.
• Producers of preservative-free allergy drops.
• Prescription ophthalmic companies offering longer-acting antihistamine products.

Competition is concentrated in the spring and summer allergy seasons. Supply continuity is therefore a commercial differentiator. A supplier able to maintain inventory before peak demand can gain share even without a stronger formulation.

What generic entry risks exist for Good Neighbor Pharmacy Eye Itch Relief?

The principal entry risks are commercial and operational rather than Paragraph IV litigation.

Price erosion

Retailers can source equivalent ketotifen products from multiple suppliers. A lower-cost supplier may force wholesale price reductions or replace the existing contract manufacturer.

Retail substitution

A pharmacy may substitute among store-brand products when the active ingredient, strength, dosage form, and labeling are equivalent. Brand recognition is weaker than in prescription ophthalmology.

Premium migration

Consumers with dry eye or contact-lens concerns may shift toward preservative-free products. A preserved product can lose higher-frequency users even if its unit price is lower.

Quality-event exposure

Ophthalmic recalls can damage a private-label brand across a large retail network. Container defects, particulate contamination, failed sterility testing, or preservative-performance failures have disproportionate commercial effects.

Seasonal forecasting

Demand volatility creates excess inventory risk after allergy season and stockout risk during pollen peaks. A retailer with better demand planning can improve margins without changing the formulation.

What licensing deals and commercial agreements matter?

Publicly visible licensing arrangements are less likely to define the product than private-label supply contracts. The key agreements typically include:

• Contract manufacturing and supply.
• Trademark and private-label brand use.
• Retail distribution.
• Exclusive or preferred wholesaler sourcing.
• Packaging ownership.
• Regulatory responsibility.
• Product recall allocation.
• Forecasting and minimum purchase commitments.
• Technology licenses for preservative-free packaging.

The highest-value negotiation points are supply continuity, change-control rights, secondary sourcing, quality-event liability, and ownership of formulation or package improvements. A retailer should avoid dependence on a single sterile ophthalmic supplier unless the agreement includes validated backup capacity.

What FDA regulatory status applies?

Ketotifen ophthalmic products are regulated as OTC ophthalmic allergy products. The label must accurately state the active ingredient, purpose, uses, warnings, directions, inactive ingredients, storage conditions, and age restrictions applicable to the product.

Regulatory priorities include:

• Sterility assurance.
• Compliance with current good manufacturing practice.
• Accurate OTC Drug Facts labeling.
• Stability through the labeled expiration period.
• Correct preservative declaration.
• Appropriate contact-lens instructions.
• Consistent NDC and package presentation.
• Adverse-event and complaint surveillance.

A reformulation involving the preservative system, container, pH, concentration, or delivery device can trigger substantial regulatory work. The lower-cost route is usually to preserve the established formulation and pursue a separately managed premium line extension.

Key Takeaways

• Good Neighbor Pharmacy Eye Itch Relief is primarily a ketotifen 0.025% private-label ophthalmic product.
• Its core commercial advantage is price and pharmacy distribution, not active-ingredient exclusivity.
• A conventional preserved multidose formulation offers the strongest cost position.
• Preservative-free ketotifen is the clearest premium opportunity, but it requires specialized multidose or unit-dose packaging.
• The strongest potential IP is likely to involve delivery systems, container technology, or formulation-packaging combinations.
• Orange Book and Paragraph IV mechanisms are generally less central than OTC labeling, sterile manufacturing, supplier agreements, and retail access.
• The principal risks are price erosion, retailer substitution, seasonal supply failures, and ophthalmic quality events.
• A two-tier portfolio, combining a low-cost preserved product with a premium preservative-free product, offers the most credible commercial expansion strategy.

FAQs

Can Good Neighbor Pharmacy Eye Itch Relief be reformulated without changing the active ingredient?

Yes. Potential changes include preservative removal, pH optimization, tonicity adjustment, viscosity control, and container redesign. Each change requires appropriate stability, sterility, compatibility, and regulatory evaluation.

Is benzalkonium chloride a competitive weakness for ketotifen eye drops?

It can be. Benzalkonium chloride supports low-cost multidose packaging but may be less attractive to consumers requiring frequent use or managing dry-eye symptoms. This creates a market opening for preservative-free packaging.

Can a private-label ketotifen formulation receive patent protection?

Yes, but basic ketotifen in water is unlikely to provide strong new-product protection. More defensible claims would focus on a specific excipient range, preservative-free multidose system, drop-control mechanism, stability result, or formulation-packaging combination.

What is the best packaging for preservative-free ketotifen?

Unit-dose containers provide a straightforward sterility strategy but increase packaging and handling costs. A validated multidose system with microbial-ingress protection can improve convenience and margin but requires more complex development and performance testing.

Does Good Neighbor Pharmacy Eye Itch Relief compete directly with prescription allergy drops?

Yes, in the consumer segment seeking relief from ocular itching. Prescription products may retain advantages in duration of action, clinical positioning, or broader allergy management, while ketotifen OTC products compete on accessibility, price, and self-care convenience.

References

1. U.S. Food and Drug Administration. (n.d.). Drug facts label for ketotifen fumarate ophthalmic solution, 0.025%. DailyMed.

2. U.S. Food and Drug Administration. (n.d.). OTC monograph M014: Ophthalmic drug products for over-the-counter human use. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2024). Current good manufacturing practice for finished pharmaceuticals, 21 C.F.R. Parts 210 and 211. Electronic Code of Federal Regulations.

4. U.S. Food and Drug Administration. (2024). Current good manufacturing practice, quality control, and testing requirements for ophthalmic drug products. U.S. Department of Health and Human Services.

5. U.S. Pharmacopeia. (2024). United States Pharmacopeia and National Formulary: Ophthalmic preparations and sterile products. United States Pharmacopeial Convention.